The online version of this article (doi:10.1186/1471-2253-14-120) contains supplementary material, which is available to authorized users.
Marc Giménez-Milà, Sebastián Videla contributed equally to this work.
S.V. has received a fee for collaborating with Laboratorios Dr Esteve in pain area. This work has not received funding. The authors declare that they have no competing interests
MG-M, CB and SV designed and wrote the study protocol. MAN, AF, AO, AB and LAM visited, monitored and followed up the patients, and applied the capsaicin patch. MG-M, CH-C and SV performed the statistical analysis and updated the database; all the authors participated in the analysis and interpretation of the data. MG-M, CH-C and SV drafted the manuscript, and all the authors reviewed it critically for important intellectual content. All the authors read and approved the final version of the manuscript.
High-concentration-capsaicin-patches (Qutenza®) have been put on the market as a treatment for peripheral neuropathic pain. A minimum infrastructure and a determinate skill set for its application are required. Our aim was to assess the feasibility of treatment with high-concentration-capsaicin-patches in clinical practice in a variety of refractory peripheral neuropathic pain syndromes in non-diabetic patients.
Observational, prospective, single-center study of patients attended to in the Pain Unit of a tertiary hospital, ≥18 year-old non-responders to multimodal analgesia of both genders. The feasibility for the application of capsaicin patch in clinical practice was evaluated by means of the number of patients controlled per day when this one was applied and by means of the times used for patch application.
Between October 2010 and September 2011, 20 consecutive non-diabetic patients (7 males, 13 females) with different diagnoses of refractory peripheral neuropathic pain syndromes, with a median (range) age of 60 (33–88) years-old were treated with a single patch application. The median (range) number of patients monitored per day was not modified when the capsaicin patch was applied [27 (26–29)] in comparison with it was not applied [28 (26–30)]. The median (range) total time to determine and mark the painful area was 9 (6–15) minutes and of patch application was 60 (58–65) minutes. No important adverse reactions were observed.
High-concentration-capsaicin-patch treatment was feasible in our unit for the treatment of a population with refractory peripheral neuropathic pain. The routine of our unit was not affected by its use.
Jackson KC: Pharmacotherapy for neuropathic pain. Pain Pract. 2006, 1: 27-33. CrossRef
Dworkin RH, O'Connor AB, Backonja M, Farrar JT, Finnerup NB, Jensen TS, Kalso EA, Loeser JD, Miaskowski C, Nurmikko TJ, Portenoy RK, Rice AS, Stacey BR, Treede RD, Turk DC, Wallace MS: Pharmacologic management of neuropathic pain: Evidence-based recommendations. Pain. 2007, 132 (3): 237-251. 10.1016/j.pain.2007.08.033. CrossRefPubMed
Moulin DE, Clark AJ, Gilron I, Ware MA, Watson CP, Sessle BJ, Coderre T, Morley-Forster PK, Stinson J, Boulanger A, Peng P, Finley GA, Taenzer P, Squire P, Dion D, Cholkan A, Gilani A, Gordon A, Henry J, Jovey R, Lynch M, Mailis-Gagnon A, Panju A, Rollman GB, Velly A: Pharmacological management of chronic neuropathic pain - consensus statement and guidelines from the canadian pain society. Pain Res Manag. 2007, 12 (1): 13-21. CrossRefPubMedPubMedCentral
Qutenza. Summary of Product Characteristics. http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/000909/WC500040453.pdf [accessed 16.12.14]
Darba J, Kaskens L, Perez-Alvarez N: Neuropathic pain: a budget impact analysis to estimate costs due to the introduction of Qutenza® on the Spanish market. Value Health. 2011, 14: A411- CrossRef
Clifford DB, Simpson DM, Brown S, Moyle G, Brew BJ, Conway B, Tobias JK, Vanhove GF: A randomized, double-blind, controlled study of NGX-4010, a capsaicin 8% dermal patch, for the treatment of painful HIV-associated distal sensory polyneuropathy. J Acquir Immune Defic Syndr. 2012, 59 (2): 126-133. 10.1097/QAI.0b013e31823e31f7. CrossRefPubMed
Qutenza, capsaicin. EPAR (European Public Assessment Report) summary for the public. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/000909/WC500040448.pdf [accessed 16.12.14]
- Assessment of the feasibility of high-concentration capsaicin patches in the pain unit of a tertiary hospital for a population of mixed refractory peripheral neuropathic pain syndromes in Non-diabetic patients
- BioMed Central
Neu im Fachgebiet AINS
Meistgelesene Bücher aus dem Fachgebiet AINS
Mail Icon II